Tearsheet

Zhengye Biotechnology (ZYBT)

Market Price (10/31/2025): $2.32 | Market Cap: $-
Sector: Health Care | Industry: Pharmaceuticals

Zhengye Biotechnology (ZYBT)

Market Price (10/31/2025): $2.32
Market Cap: $-
Sector: Health Care
Industry: Pharmaceuticals

Market Valuation & Key Metrics

Valuation
Key Metrics

	10/31/25	2024	2023	2022
Share Price CYE	$2.32
Market Cap CYE ($ Bil)	0.0	-	-	-
Total Debt ($ Bil)	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	0.1	0.0	0.0
Enterprise Value ($ Bil)	0.0
Valuation Ratios
P/S TTM	0.0	0.0	0.0	0.0
P/EBIT TTM	0.0	0.0	0.0	0.0
P/E TTM	0.0	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	3.0	3.0	2.8	2.7
P/EBIT TTM (Sector)	6.8	6.8	7.0	6.2
P/E TTM (Sector)	11.8	11.5	10.1	9.3

	10/31/25	2024	2023
Share Price CYE	$2.32
Market Cap CYE ($ Bil)	0.0	-	-
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	0.1	0.0
Enterprise Value ($ Bil)	0.0
Valuation Ratios
P/S TTM	0.0	0.0	0.0
P/EBIT TTM	0.0	0.0	0.0
P/E TTM	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	3.0	3.0	2.8
P/EBIT TTM (Sector)	6.8	6.8	7.0
P/E TTM (Sector)	11.8	11.5	10.1

null

ZYBT Stock

Return (1M):

null

Factor Drivers of Stock Movement

null

null

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ZYBT Return	-	-	-	-	-	-	0%
Peers Return	-10%	-6%	-26%	-27%	-27%	2488%	759%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	110%
Monthly Win Rates [3]
ZYBT Win Rate	-	-	-	-	-	38%
Peers Win Rate	22%	30%	22%	23%	32%	44%
S&P 500 Win Rate	58%	75%	42%	67%	75%	67%
Max Drawdowns [4]
ZYBT Max Drawdown	-	-	-	-	-	-
Peers Max Drawdown	-17%	-13%	-31%	-34%	-35%	-27%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: BGM, NSRX, RGC, RHHBY, SXTC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

ZYBT has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique Key	Event	XLV	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-16.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	19.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	599 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-28.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	40.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	116 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-15.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	18.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	326 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-40.6%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	68.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1100 days	1480 days

Compare to

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Zhengye Biotechnology (ZYBT)

Business Description

We, through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, the operating entity has been committed to enhancing the health of livestock. The operating entity markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 29 provincial regions across China and are exported overseas, to Vietnam, Pakistan, and Egypt. Our principal executive offices are located at No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, China. Our registered office in the Cayman Islands is located at 3-212 Governors Square, 23 Lime Tree Bay Avenue, P.O. Box 30746, Seven Mile Beach, Grand Cayman KY1-1203, Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168.

	Best Bets In Health Care Sector
What You Pay
P/E	�	15.3	14.1	12.3	15.4	14.0	14.0	13.6	12.8	11.8	12.4
P/EBIT	�	8.1	11.0	10.5	9.3	9.6	9.0	10.1	10.3	29.2	10.3
What You Get
Rev Chg Q	�	7.7%	40.8%	19.4%	2.8%	-4.1%	-6.6%	2.8%	10.3%	11.9%	-4.8%
Rev Chg LTM	�	3.0%	35.0%	28.5%	1.3%	5.7%	0.6%	4.8%	13.5%	9.1%	-3.3%
Rev Chg 3Y Avg	�	0.8%	35.5%	49.9%	1.0%	34.3%	0.8%	-0.9%	-12.4%	3.0%	-3.0%
FCF/Rev 3Y Avg	�	113.4%	43.4%	38.9%	29.0%	26.1%	21.6%	17.0%	13.8%	11.9%	9.0%

Trade Ideas

Select past ideas related to ZYBT. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	4.2%	4.2%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.3%	16.3%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.8%	3.8%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.0%	14.0%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	13.5%	13.5%	-8.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	4.2%	4.2%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.3%	16.3%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.8%	3.8%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.0%	14.0%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	13.5%	13.5%	-8.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	279.1%	161.2%
2	INBX	Inhibrx Biosciences	131.0%	409.8%
3	PUMP	ProPetro	99.6%	16.2%
4	DYN	Dyne Therapeutics	88.4%	-0.0%
5	VICR	Vicor	85.4%	89.2%
6	CELC	Celcuity	74.6%	503.2%
7	GLUE	Monte Rosa Therapeutics	73.5%	87.5%
8	NVTS	Navitas Semiconductor	72.1%	251.8%
9	LUMN	Lumen Technologies	70.3%	94.7%
10	BALY	Ballys	63.4%	4.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	-62.9%	5106.3%
2	LRN	Stride	-53.8%	-35.8%
3	FMC	FMC	-51.0%	-66.6%
4	FI	Fiserv	-48.3%	-68.3%
5	NFE	New Fortress Energy	-43.6%	-91.9%
6	VG	Venture Global	-41.7%
7	OGN	Organon	-40.2%	-55.0%
8	VRNS	Varonis Systems	-39.5%	-21.2%
9	ITGR	Integer	-38.5%	-52.2%
10	LENZ	LENZ Therapeutics	-37.9%	5.5%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

Peer Comparisons for Zhengye Biotechnology

Financials

	ZYBT	BGM	NSRX	RGC	RHHBY	SXTC	Median
Name	Zhengye .	BGM	Nasus Ph.	Regencel.	Roche	China SX.
Mkt Price	2.35	9.12	7.78	16.35	40.56	1.36	8.45
Mkt Cap	-	-	-	-	-	-	-
Rev LTM	-	-	-	-	-	-	-
Op Inc LTM	-	-	-	-	-	-	-
FCF LTM	-	-	-	-	-	-	-
FCF 3Y Avg	-	-	-	-	-	-	-
CFO LTM	-	-	-	-	-	-	-
CFO 3Y Avg	-	-	-	-	-	-	-

Growth & Margins

	ZYBT	BGM	NSRX	RGC	RHHBY	SXTC	Median
Name	Zhengye .	BGM	Nasus Ph.	Regencel.	Roche	China SX.
Rev Chg LTM	-	-	-	-	-	-	-
Rev Chg 3Y Avg	-	-	-	-	-	-	-
Rev Chg Q	-	-	-	-	-	-	-
QoQ Delta Rev Chg LTM	-	-	-	-	-	-	-
Op Mgn LTM	-	-	-	-	-	-	-
Op Mgn 3Y Avg	-	-	-	-	-	-	-
QoQ Delta Op Mgn LTM	-	-	-	-	-	-	-
CFO/Rev LTM	-	-	-	-	-	-	-
CFO/Rev 3Y Avg	-	-	-	-	-	-	-
FCF/Rev LTM	-	-	-	-	-	-	-
FCF/Rev 3Y Avg	-	-	-	-	-	-	-

Valuation

	ZYBT	BGM	NSRX	RGC	RHHBY	SXTC	Median
Name	Zhengye .	BGM	Nasus Ph.	Regencel.	Roche	China SX.
Mkt Cap	-	-	-	-	-	-	-
P/S	-	-	-	-	-	-	-
P/EBIT	-	-	-	-	-	-	-
P/E	-	-	-	-	-	-	-
P/CFO	-	-	-	-	-	-	-
Total Yield	-	-	-	-	-	-	-
Dividend Yield	-	-	-	-	-	-	-
FCF Yield 3Y Avg	-	-	-	-	-	-	-
D/E	-	-	-	-	-	-	-
Net D/E	-	-	-	-	-	-	-

Returns

	ZYBT	BGM	NSRX	RGC	RHHBY	SXTC	Median
Name	Zhengye .	BGM	Nasus Ph.	Regencel.	Roche	China SX.
1M Rtn	-10.3%	-10.9%	17.0%	5.8%	-3.0%	-13.4%	-6.6%
3M Rtn	-57.5%	7.8%	-	23.9%	4.2%	-12.8%	4.2%
6M Rtn	-77.5%	-19.3%	-	706.9%	2.5%	-38.7%	-19.3%
12M Rtn	-	23.1%	-	8,893.4%	6.2%	-70.6%	14.6%
3Y Rtn	-	-	-	2,156.1%	14.1%	-98.9%	14.1%
1M Excs Rtn	-4.9%	-12.2%	28.0%	1.6%	-11.2%	-16.7%	-8.1%
3M Excs Rtn	-65.0%	-3.3%	-	16.7%	-4.9%	-29.4%	-4.9%
6M Excs Rtn	-99.2%	-41.0%	-	685.2%	-19.3%	-60.5%	-41.0%
12M Excs Rtn	-	-0.8%	-	10,069.8%	-13.2%	-88.3%	-7.0%
3Y Excs Rtn	-	-	-	2,079.3%	-63.7%	-175.7%	-63.7%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021
Period End	0/0/-1	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Filing Date	0/0/-1	7/3/2025	1/7/2025	1/9/2024	1/9/2024
Key Financials
Total Revenue	-	186	212	260	214
EBITDA	-	43	72	86	70
Operating Income	-	17	48	66	56
Net Income	-	11	31	47	39
EPS	-	0.24	0.67	0.99	0.83
Growth Rates
Total Revenue Growth	-	-12.0%	-18.7%	21.6%	-
EBITDA Growth	-	-40.9%	-15.7%	22.0%	-
Operating Income Growth	-	-64.0%	-27.9%	18.9%	-
Net Income Growth	-	-64.0%	-32.7%	20.0%	-
Margins
EBITDA Margin	-	22.9%	34.1%	32.9%	32.8%
Operating Income Margin	-	9.2%	22.5%	25.4%	26.0%
Net Income Margin	-	6.1%	14.9%	18.0%	18.2%
Cash & Debt
Total Cash	�	20	16	10	6
Total Debt	0	86	90	65	30
Net Debt / (Cash)	�	66	74	55	24
Cash Flows
Net Cash from Operations	-	41	48	17	32
Free Cash from Operations	-	13	37	-10	5
Returns to Shareholders
Dividends	0	16	39	21	11
Share Repurchases	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31
Period End
Filing Date
Key Financials Quarterly
Total Revenue
Ebitda
Operating Income
Net Income
EPS
Key Financials TTM
Total Revenue TTM
Ebitda TTM
Operating Income TTM
Net Income TTM
Growth Rates Quarterly
Total Revenue Growth
EBITDA Growth
Operating Income Growth
Net Income Growth
Margins Quarterly
EBITDA Margin
Operating Income Margin
Net Income Margin
Cash & Debt
Total Cash
Total Debt
Net Debt / (Cash)
Cash Flows Quarterly
FCF from Operations
Cash Flows TTM
FCF from Operations TTM
Returns to Shareholders Quarterly
Dividends
Share Repurchases
Return on Invested Capital (ROIC) Quarterly
ROIC
Return on Invested Capital (ROIC) TTM
ROIC TTM

	1M	2M	3M	6M	1Y	3Y
Beta	-3.00	2.57	3.29	1.51	0.29	0.28
Up Beta	-50.92	1.67	2.81	1.86	1.93	-0.28
Down Beta	-17.69	-0.12	2.94	0.70	0.12	-0.52
Up Capture	-594%	-10%	41%	45%	82%	7%
Bmk +ve Days	13	23	35	74	144	420
Stock +ve Days	8	21	29	61	92	92
Down Capture	2147%	710%	619%	193%	137%	86%
Bmk -ve Days	8	19	29	52	107	330
Stock -ve Days	13	21	32	62	87	87

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	163,921
Short Interest: % Change Since 9302025	-3.5%
Average Daily Volume	291,646
Days-to-Cover Short Interest	1

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12312024	7032025	20-F 12/31/2024
12312023	1072025	424B4 12/31/2023
12312022	1092024	F-1 12/31/2022

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Zhengye Biotechnology (ZYBT)

Market Price (10/31/2025): $2.32 | Market Cap: $-Sector: Health Care | Industry: Pharmaceuticals

Zhengye Biotechnology (ZYBT)

Market Price (10/31/2025): $2.32Market Cap: $-Sector: Health CareIndustry: Pharmaceuticals

Market Valuation & Key Metrics

ZYBT Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Zhengye Biotechnology (ZYBT)

Interactive Breakdown

Better Bets than Zhengye Biotechnology (ZYBT)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Zhengye Biotechnology

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (10/31/2025): $2.32 | Market Cap: $-
Sector: Health Care | Industry: Pharmaceuticals

Market Price (10/31/2025): $2.32
Market Cap: $-
Sector: Health Care
Industry: Pharmaceuticals